title: Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.
abstract: A small molecule compound, JTP-74057/GSK1120212/trametinib, had been discovered as a very potent antiproliferative agent able to induce the accumulation of CDK inhibitor p15INK4b. To conduct its drug development rationally as an anticancer agent, molecular targets of this compound were identified as MEK1/2 using compound-affinity chromatography. It was shown that JTP-74057 directly bound to MEK1 and MEK2 and allosterically inhibited their kinase activities, and that its inhibitory characteristics were similar to those of the known and different chemotype of MEK inhibitors PD0325901 and U0126. It was further shown that JTP-74057 induced rapid and sustained dephosphorylation of phosphorylated MEK in HT-29 colon and other cancer cell lines, while this decrease in phosphorylated MEK was not observed in PD0325901-treated cancer cells. Physicochemical analyses revealed that JTP-74057 preferentially binds to unphosphorylated MEK (u-MEK) in unique characteristics of both high affinity based on extremely low dissociation rates and ability stabilizing u-MEK with high thermal shift, which were markedly different from PD0325901. These findings indicate that JTP-74057 is a novel MEK inhibitor able to sustain MEK to be an unphosphorylated form resulting in pronounced suppression of the downstream signaling pathways involved in cellular proliferation.
authors.affiliation: Pharmaceutical Frontier Research Laboratories, Central Pharmaceutical Institute, Japan Tobacco, Kanazawa-ku, Yokohama, Kanagawa, Japan.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Yoshida
authors.forename: Junya
authors.initials: J
authors.lastname: Kakegawa
authors.forename: Takayuki
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Yoshiji
authors.initials: Y
authors.lastname: Hantani
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Okajima
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Sakai
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Motonao
authors.initials: M
authors.lastname: Nakamura
mesh_terms: D000494:Allosteric Regulation; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology; D002070:Butadienes / Q000494:pharmacology; D002846:Chromatography, Affinity; D004159:Diphenylamine / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D057809:HEK293 Cells; D019073:HT29 Cells; D006801:Humans; D007700:Kinetics; D048369:MAP Kinase Kinase 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D048370:MAP Kinase Kinase 2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015394:Molecular Structure; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000201:enzymology* / Q000473:pathology; D009570:Nitriles / Q000494:pharmacology; D010766:Phosphorylation; D011485:Protein Binding; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D011728:Pyridones / Q000737:chemistry / Q000494:pharmacology*; D011744:Pyrimidinones / Q000737:chemistry / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D002070:Butadienes; D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011728:Pyridones; D011744:Pyrimidinones; C113580:U 0126; C560077:trametinib; C506614:mirdametinib; D004159:Diphenylamine; C482128:MAP2K2 protein, human; D048369:MAP Kinase Kinase 1; D048370:MAP Kinase Kinase 2; C482125:MAP2K1 protein, human